	US 12,465,605 B2
	Methods and materials for gender-dependent treatment of cardiovascular dysfunction
Jordan D. Miller, Rochester, MN (US); Maurice E. Enriquez-Sarano, Rochester, MN (US); Bin Zhang, Rochester, MN (US); and Carolyn Marie Roos, Rochester, MN (US)
Assigned to Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Appl. No. 17/602,412
Filed by Mayo Foundation for Medical Education and Research, Rochester, MN (US)
PCT Filed Apr. 10, 2020, PCT No. PCT/US2020/027777 § 371(c)(1), (2) Date Oct. 8, 2021, PCT Pub. No. WO2020/210707, PCT Pub. Date Oct. 15, 2020.
Claims priority of provisional application 62/832,139, filed on Apr. 10, 2019.
Prior Publication US 2022/0211702 A1, Jul. 7, 2022
Int. Cl. A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 31/635 (2006.01); A61K 45/06 (2006.01); A61P 9/04 (2006.01); A61P 9/10 (2006.01); A61P 9/12 (2006.01)

CPC A61K 31/506 (2013.01) [A61K 31/5377 (2013.01); A61K 31/635 (2013.01); A61K 45/06 (2013.01); A61P 9/04 (2018.01); A61P 9/10 (2018.01); A61P 9/12 (2018.01)]

19 Claims

1. A method for treating a mammal on a basis of the mammal's gender, said method comprising:

(a) identifying a mammal as having, or as being at risk of developing, heart valve calcification or vessel calcification,

(b) identifying said mammal as a male mammal or a female mammal, and

(c) when said mammal is a male mammal, administering a sGC agonist to said male mammal, thereby slowing progression of calcification of a heart valve or vessel within said male mammal, and when said mammal is a female mammal, not administering said sGC agonist to said female mammal, wherein said sGC agonist is ataciguat (5-chloro-2-[[(5-chloro-2-thienyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl) phenyl]-benzamide; HMR1766).